spacer
home > pmps > autumn 2003 > who nose how far nasal delivery can go?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Who Nose How Far Nasal Delivery Can Go?

Nasal delivery has traditionally been restricted to topically acting substances used to treat the common cold and nasal allergies. Recently however, there has been increased interest in the nose as an alternative to oral delivery and injection for many systemic drugs and vaccines. The highly vascularised and immunogenic nasal mucosa offers potential advantages in terms of quick action, improved bio-availability and patient compliance as well as improved immune response for vaccines.

Faced with surging drug development costs and fierce generic competition, pharmaceutical companies are under increasing pressure to find ways to increase and prolong the profitability of both existing and new products. In addition, many of the advanced molecules being developed by biotechnology companies require more efficient delivery than that offered by conventional delivery routes and systems. The challenge of optimising the bio-availability and patient compliance of these expensive molecules are other significant drivers for the development of novel drug delivery systems. If successful, reformulation allied with novel delivery systems provide powerful tools for improving efficiency and differentiating a product from those of competitors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Per Gisle Djupesland, Head of R&D and Co-Founder of OptiNose AS

Dr Per Gisle Djupesland is Co-Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing a novel concept for nasal delivery of drugs and vaccines. He is a specialist in Otorhinolaryngology with a PhD in Nasal Physiology from the University of Oslo and has been Research Fellow at the University of Toronto, Canada. He has a degree in International Health and Tropical Medicine from Paris, France, and has been Project Manager for a large-scale vaccination trial in the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement